Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune checkpoint inhibition, supported by anticipated approvals of multiple PD1 and PDL1 inhibitors from multinational and domestic developers. In parallel, biomarkerdriven therapies are strengthening precision treatment options, exemplified by Janssen’s Balversa (erdafitinib), approved for patients with susceptible FGFR3 mutations following progression on prior PD1 or PDL1 therapy. Over the tenyear forecast period, latestage and regulatoryphase assets—including Suzhou Suncadia Biopharmaceutal’s SHR-A2102 in perioperative muscleinvasive disease, RemeGen’s disitamab vedotin in HER2expressing urothelial carcinoma, and Pfizer’s subcutaneous sasanlimab in highrisk NMIBC—will further diversify treatment options, particularly in settings where relapse rates remain high. Despite these advances, a substantial unmet need persists among patients who progress after multiple lines of therapy and those ineligible for intensive systemic treatment. This report evaluates China’s evolving bladder cancer treatment landscape, assesses the commercial outlook for current and emerging therapies, and examines how NRDL inclusion and volumebased procurement dynamics may shape future launch and uptake over the forecast period.
QUESTIONS ANSWERED
- What is the size of the clinically and commercially relevant drug-treatable bladder cancer population, and how is the disease currently managed?
- What are the key unmet needs in the management of bladder cancer?
- Which are the key future players, and what factors are driving growth in the bladder cancer market?
- What are the interviewed experts’ insights into new and existing therapies?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
Release date: July 2026
Geography: China (urban / rural)
Primary research: Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 medical oncologists and 25 urologists in China
Epidemiology: Diagnosed incidence of bladder cancer in urban versus rural China, clinically relevant and market-relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient share of key bladder cancer therapies through 2035, based on primary and secondary market research to formulate bottom-up assumptions
Drug treatments: Coverage of key current and late-phase emerging therapies
Custom drug modeler: Integrated tool to input customized forecast assumptions (e.g., launch date, price)
